You are here

Responses

Article menu

Download PDFPDF

XML
Epidemiology/Health Services Research
Real-world evidence on sodium-glucose cotransporter-2 inhibitor use and risk of Fournier’s gangrene
Compose a Response to This Article
Compose Response

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on: 21 February 2020
    Experience of SGLT2 inhibitors , Safety and side effect profile

    Dear Editor
    This indeed a very good article on emerging class of antidiabetic drugs i.e SGLT2 inhibitors. SGLT2 inhibitors are making their way not only for their role as an adjuvant therapy for control of diabetes, but their beneficial role in providing cardiac safety, renal protection and weight reduction are making these drugs superior in comparison to DPP4 inhibitors, which are another widely used and well tolerated anti diabetic drugs. SGLT2 inhibitors are known to lower blood glucose by inhibiting glucose and sodium re absorption and promoting glycosuria, as a consequence they cause glucose and HbA1C reduction and lowering of blood pressure1. A part from these benefits , SGLT2 inhibitors might acquire potential indication to be used for prevention and treatment of gout due to their uric acid reducing properties2.
    Since these drugs got FDA approval and become available, the side effect profile of these drugs have always remained talk of major debates. Well known side effects are genital infection, increase incidence of mycotic infections and diabetic ketoacidosis. One of the major and serious concern with use of SGLT2 inhibitors is possibility of Fournier’s gangrene. Fournier’s gangrene is an extremely rare but life-threatening bacterial infection of the genital tissue. Current article is also reflection of my own experience. I have been prescribing SGLT2 inhibitors quite frequently and most of the patients are in regular follow up and I have not seen any...

    Show More
    Conflict of Interest:
    None declared.